AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7633972
Drug: Ticlopidine 250
RxNorm normalized name: ticlopidine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine 250 mg bd
Trial: 31010516
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy by vascular surgery
Trial: 31010516
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy by interventional cardiology
Trial: 31010516
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy by interventional radiology
Trial: 31010516
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy by other specialties
Trial: 28183564
Drug: Tramadol+paracetamol (Zaldiar;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol+paracetamol (Zaldiar; 325 mg paracetamol, 37.5 mg tramadol)
Trial: 23708155
Drug: G‐CSF‐mediated stem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF‐mediated stem cell mobilization, apheresis, and intramyocardial injection of 1 × 10(5) autologous CD34(+) cells/kg
Trial: 23708155
Drug: G‐CSF‐mediated stem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF‐mediated stem cell mobilization, apheresis, and intramyocardial placebo injection
Trial: 11401931
Drug: Intravenous glycoprotein
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glycoprotein IIb/IIIa inhibitor (12 patients, 86%)
Trial: 9040650
Drug: High-dose immunoglobulins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose immunoglobulins (IVIg)
Trial: 7510155
Drug: Albumin excretion
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin excretion (marker of glomerulum)
Trial: 20876343
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg once daily with low-sodium diet
Trial: 20876343
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg once daily with high-sodium diet
Trial: 15937679
Drug: Triiodothyronine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triiodothyronine treatment (1 microg/kg IV bolus followed by 0.06 microg/kg/hr continuous perfusion)
Trial: 15937679
Drug: Standard support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard support treatment (0.9% ClNa delivered over 270 min)
Trial: 15937679
Drug: Triiodothyronine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triiodothyronine treatment
Trial: 15937679
Drug: Standard support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard support treatment
Trial: 15937679
Drug: Triiodothyronine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triiodothyronine treatment and Standard support treatment
Trial: 8636743
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin (100 mg/m2) plus epidoxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2)
Trial: 8636743
Drug: Low-dose cisplatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cisplatin (50 mg/m2) plus epidoxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2)
Trial: 8636743
Drug: Low-dose cisplatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cisplatin (50 mg/m2)
Trial: 1731134
Drug: DTP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP and PRP-T given at separate injection sites (group 2)
Trial: 6147691
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic chemotherapy
Trial: 6147691
Drug: Prophylactic chemotherapy
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic chemotherapy
Trial: 21291037
Drug: Controlled ovarian
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ovarian hyperstimulation (COH) treatment
Trial: 18565634
Drug: Marlboro Lights
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marlboro Lights (ML)
Trial: 12588385
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg three times a day for 2 weeks
Trial: 12588385
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet three times a day for 2 weeks
Trial: 11092773
Drug: Intravenous sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sedation with midazolam
Trial: 11092773
Drug: Local anaesthesia
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthesia and intravenous sedation
Trial: 29930161
Drug: Ramipril (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (6 mg/m2 per day)
Trial: 29930161
Drug: Ramipril therapy
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril therapy with proteinuria reduction <30%
Trial: 29930161
Drug: Ramipril therapy
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril therapy with proteinuria reduction 30%-60%
Trial: 29930161
Drug: Ramipril therapy
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril therapy with proteinuria reduction >60%
Trial: 25416925
Drug: Saline isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline isotonic solution
Trial: 17386354
Drug: zofenopril (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zofenopril (15 to 30 mg/d)
Trial: 17386354
Drug: ramipril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril (2.5 to 5 mg/d)
Trial: 10691158
Drug: Rosiglitazone 1
RxNorm normalized name: rosiglitazone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 1 mg plus sulphonylurea
Trial: 10691158
Drug: Rosiglitazone 2
RxNorm normalized name: rosiglitazone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 2 mg plus sulphonylurea
Trial: 3079939
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg GTN spray
Trial: 3079939
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg GTN spray
Trial: 3079939
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg GTN spray
Trial: 3079939
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg sublingual GTN
Trial: 31714954
Drug: Cotrimoxazole preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole preventive therapy (CPT) continued
Trial: 31714954
Drug: Cotrimoxazole preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole preventive therapy (CPT) discontinued (placebo)
Trial: 26740684
Drug: LNS intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LNS intervention groups (10 g, 20 g, 40 g)
Trial: 22709949
Drug: 23vPPS vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23vPPS vaccine (Pneumovax(®))
Trial: 22709949
Drug: inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactivated influenza vaccine (Fluarix(®))
Trial: 15866560
Drug: Orlistat plus
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat plus CBTgsh (120 mg three times a day)
Trial: 12570939
Drug: eptifibatide plus
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eptifibatide plus unfractionated heparin
Trial: 10554416
Drug: Nisoldipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (10 mg/day for 2 weeks before surgery)
Trial: 1858442
Drug: Ibuprofen 1800-2400
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 1800-2400 mg per day for 3 weeks
Trial: 28052714
Drug: Rectal ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rectal ibuprofen
Trial: 25884223
Drug: EMDR (seven
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMDR (seven weekly 90 minute sessions) + TAU
Trial: 24229598
Drug: Probiotics (live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (live combined bifidobacterium and lactobacillus tablets)
Trial: 24229598
Drug: Oral immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunoglobulin (anti‐rotavirus egg yolk immunoglobulin, IgY)
Trial: 19935591
Drug: Intermittent pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pneumatic compression (IPC) therapy (1 hour/day for multiple sessions)
Trial: 19440083
Drug: Olanzapine 40
RxNorm normalized name: olanzapine 405 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 40 mg/d
Trial: 6110912
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy (nasal prongs for at least 15 h daily, usually at 2 l/min)
Trial: 25796338
Drug: Bivalent HPV‐16/18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent HPV‐16/18 vaccine
Trial: 25796338
Drug: Control Hepatitis‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Hepatitis‐A vaccine
Trial: 22878782
Drug: PE given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PE given 30 min after a liquid meal as 100-g yoghurt drink
Trial: 15297848
Drug: CC (Conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC (Conventional Chemotherapy)
Trial: 11309010
Drug: Ropivacaine 1
RxNorm normalized name: ROPivacaine 1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 1 mg/ml plus fentanyl 2 microg/ml administered via patient-controlled epidural analgesia (PCEA)
Trial: 11309010
Drug: Ropivacaine 1
RxNorm normalized name: ROPivacaine 1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 1 mg/ml plus fentanyl 2 microg/ml administered via continuous epidural infusion (CEI)
Trial: 9389843
Drug: Tramadol 2
RxNorm normalized name: traMADol 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 2 mg kg‐1 in 0.9% saline (group T)
Trial: 9389843
Drug: Bupivacaine 2
RxNorm normalized name: bupivacaine 29.3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 2 mg kg‐1 (group B)
Trial: 3123153
Drug: latamoxef (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: latamoxef (4 g/day)
Trial: 3123153
Drug: ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftriaxone (2 g/day)
Trial: 3123153
Drug: cefotaxime (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cefotaxime (4 g/day)
Trial: 28585263
Drug: Interventional sialendoscopy
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interventional sialendoscopy followed by intraductal steroid irrigations (group A)
Trial: 28031511
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TXA) 15 mg/kg 15 minutes prior to surgery
Trial: 24158412
Drug: Appropriate antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate antibiotic use according to local hospital guidelines
Trial: 24158412
Drug: Early intravenous-oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intravenous-oral switching
Trial: 21180082
Drug: Qingkailing Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingkailing Injection (QKL) plus Ertong Qingfei oral liquid
Trial: 21180082
Drug: Ribavirin injection
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin injection plus compound guaiacol potassium sulfonale oral solution
Trial: 16084850
Drug: Gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 600 mg twice daily for 5 days
Trial: 10537956
Drug: Palliative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative treatment with gemcitabine in combination with best supportive care
Trial: 7301035
Drug: Tienilic acid
RxNorm normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tienilic acid (250 mg/day)
Trial: 7301035
Drug: Chlorothiazide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorothiazide (500 mg/day)
Trial: 22101900
Drug: High-dose (HD;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (HD; 200 IU/kg/d)
Trial: 22101900
Drug: Low-dose (LD;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose (LD; 50 IU/kg 3 times/week)
Trial: 20421833
Drug: 5 mg·kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg·kg of anhydrous caffeine
Trial: 20421833
Drug: 2 mg·kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg·kg of anhydrous caffeine
Trial: 18291401
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol for prevention of PPH
Trial: 15746793
Drug: Low-dose prednisone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prednisone (control group)
Trial: 15746793
Drug: Steroid withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid withdrawal (study group)
Trial: 15746793
Drug: Steroid withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid withdrawal group (1 year follow-up)
Trial: 8630596
Drug: High-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inhaled budesonide (1,600 micrograms/d)
Trial: 8630596
Drug: Low-dose inhaled
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose inhaled budesonide (400 micrograms/d)
Trial: 8630596
Drug: Oral theophylline
RxNorm normalized name: theophylline Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral theophylline (600 mg/d)
Trial: 2857611
Drug: Idazoxan (RX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idazoxan (RX 781094), an alpha 2-antagonist, administered at low intra-arterial doses
Trial: 2857611
Drug: Idazoxan (RX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idazoxan (RX 781094), an alpha 2-antagonist, administered at higher doses
Trial: 2857611
Drug: Compounds with
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compounds with mixed alpha 2- and alpha 1-antagonist properties
Trial: 29582212
Drug: CSL112 (1.7,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL112 (1.7, 3.4, or 6.8 g)
Trial: 27097165
Drug: Benralizumab 2
RxNorm normalized name: benralizumab 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab 2 mg
Trial: 27097165
Drug: Benralizumab 20
RxNorm normalized name: benralizumab 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab 20 mg
Trial: 22710579
Drug: Lactulose (Gp‐L,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (Gp‐L, 30 ml three times per day)
Trial: 22710579
Drug: Probiotics (Gp‐P,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Gp‐P, three capsules per day containing 112.5 billion viable lyophilized bacteria per capsule)
Trial: 22710579
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (Gp‐N)
Trial: 22710579
Drug: Lactulose (Gp‐L)
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose (Gp‐L) vs Probiotics (Gp‐P)
Trial: 22710579
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Gp‐L, Gp‐P, Gp‐N)
Trial: 18706417
Drug: Ustekinumab (subcutaneous)
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab (subcutaneous)
Trial: 18706417
Drug: Ustekinumab (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (subcutaneous and intravenous)
Trial: 12698115
Drug: Infliximab (Remicade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (Remicade 3 mg/kg) intravenously over 2 hours
Trial: 1647955
Drug: Pharmacokinetically adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetically adjusted doses of metoclopramide
Trial: 1647955
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of metoclopramide adjusted to body weight
Trial: 6420904
Drug: Inhalation anaesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anaesthetic technique (Group A)
Trial: 6420904
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion technique (Group B)
Trial: 26681680
Drug: S-1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 plus oral leucovorin (LV) at 40, 50, or 60 mg according to body surface area plus LV 25 mg, both given orally twice daily for 1 week, repeated every 2 weeks (SL group)
Trial: 26681680
Drug: S-1 monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 monotherapy at the same dose as the SL group for 4 weeks, repeated every 6 weeks (S-1 group)
Trial: 26681680
Drug: S-1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 plus oral leucovorin (LV)
Trial: 15790675
Drug: Propacetamol 2
RxNorm normalized name: 1,2,3-PROPANETRIOL, 2-(4-AMINOBENZOATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol 2 g (i.v. acetaminophen 1 g formulation) administered as a 2-min bolus injection (n=50)
Trial: 15790675
Drug: Propacetamol 2
RxNorm normalized name: 1,2,3-PROPANETRIOL, 2-(4-AMINOBENZOATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol 2 g (i.v. acetaminophen 1 g formulation) administered as a 15-min infusion (n=50)
Trial: 15790675
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen 1 g (n=50)
Trial: 12213864
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone suppressive therapy for longer than 6 months
Trial: 9140241
Drug: AHA-recommended technique
RxNorm normalized name: AHA
DrugBank: Acetohydroxamic acid (DB00551)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AHA-recommended technique (apex-to-anterior electrode placement, no smearing of gel between electrodes)
Trial: 9140241
Drug: Electrode paddles
RxNorm normalized name: Paddle weed
DrugBank: Ecklonia cava (DB19252)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrode paddles adjacent, gel smeared between electrodes
Trial: 29847382
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg methadone
Trial: 29847382
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg methadone
Trial: 27080282
Drug: Background volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background volume of 5 mL/h of 0.2% ropivacaine
Trial: 27080282
Drug: Background volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background volume of 3.2 mL/h of 0.2% ropivacaine
Trial: 20216387
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion targeting 0 ng/ml
Trial: 20216387
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion targeting 2 ng/ml
Trial: 20216387
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion targeting 4 ng/ml
Trial: 17373174
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination therapy (TCT) - hydroquinone, tretinoin, and fluocinolone acetonide applied once daily
Trial: 17373174
Drug: Hydroquinone alone
RxNorm normalized name: Hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroquinone alone applied twice daily
Trial: 11250991
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy
Trial: 11250991
Drug: Four cycles
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy
Trial: 11250991
Drug: 5-day schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day schedule of BEP chemotherapy
Trial: 11250991
Drug: 3-day schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day schedule of BEP chemotherapy